![Hakim Bouterfa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hakim Bouterfa
Directeur Général chez PentixaPharm GmbH
Postes actifs de Hakim Bouterfa
Sociétés | Poste | Début | Fin |
---|---|---|---|
1717 Life Sciences Ventures GmbH | Private Equity Investor | 01/01/2017 | - |
PentixaPharm GmbH
![]() PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Directeur Général | - | - |
Historique de carrière de Hakim Bouterfa
Anciens postes connus de Hakim Bouterfa
Sociétés | Poste | Début | Fin |
---|---|---|---|
ECKERT & ZIEGLER SE | Directeur Technique/Scientifique/R&D | 01/01/2023 | 31/12/2023 |
Molecular Insight Pharmaceuticals GmbH
![]() Molecular Insight Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of Lantheus Holdings, Inc., Molecular Insight Pharmaceuticals GmbH develops and commercializes innovative molecular imaging pharmaceuticals. The company is based in Wuerzburg, Germany. | Directeur Général | - | - |
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - | - |
OctreoPharm Sciences GmbH
![]() OctreoPharm Sciences GmbH Pharmaceuticals: MajorHealth Technology OctreoPharm Sciences GmbH develops and manufactures pharmaceutical products. It operates as a clinical development biopharmaceutical company which focuses on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company was founded by Hakim Larbi Bouterfa and Udo Blaseg in 2010 and is headquartered in Berlin, Germany. | Fondateur | 01/01/2009 | - |
Statistiques
Internationale
Allemagne | 6 |
Autriche | 2 |
Opérationnelle
Chief Executive Officer | 2 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Finance | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ECKERT & ZIEGLER SE | Health Technology |
Entreprise privées | 5 |
---|---|
OctreoPharm Sciences GmbH
![]() OctreoPharm Sciences GmbH Pharmaceuticals: MajorHealth Technology OctreoPharm Sciences GmbH develops and manufactures pharmaceutical products. It operates as a clinical development biopharmaceutical company which focuses on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company was founded by Hakim Larbi Bouterfa and Udo Blaseg in 2010 and is headquartered in Berlin, Germany. | Health Technology |
Molecular Insight Pharmaceuticals GmbH
![]() Molecular Insight Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of Lantheus Holdings, Inc., Molecular Insight Pharmaceuticals GmbH develops and commercializes innovative molecular imaging pharmaceuticals. The company is based in Wuerzburg, Germany. | Health Technology |
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. | Health Technology |
1717 Life Sciences Ventures GmbH | Finance |
PentixaPharm GmbH
![]() PentixaPharm GmbH Miscellaneous Commercial ServicesCommercial Services Pentixapharm GmbH engages in the development, production, marketing, and distribution of medicines and radiopharmaceutical products, which act on the CXCR4 receptor. The company was founded on May 14, 2019 and is headquartered in Wuerzburg, Germany. | Commercial Services |
- Bourse
- Insiders
- Hakim Bouterfa
- Expérience